Cardiovascular Effects of Metformin on Obesity

Summary

It has been shown that asymptomatic obese adolescents can demonstrate abnormal regional myocardial contraction, with preserved global cardiac function. Metformin has been shown to decrease cardiovascular mortality in patients with type 2 diabetes and insulin resistance, but the mechanism of cardiovascular protection is unknown. The purpose of this study is to evaluate the reversibility of subclinical cardiovascular abnormalities in obese adolescents with insulin resistance after a six-month course of Metformin. The investigators hypothesized that the beneficial effects of Metformin will be progressive and sustained after six months of therapy.

Timeline

Start

2015-04

Primary completion

2016-10

Completion

2016-10

Outcome

Outcome not reported

Stopped (Business): “No funding”

Drugs

Indications

No indication recorded.